rosuvastatin
Crestor (rosuvastatin) is a statin that lowers LDL cholesterol by slowing its production in the liver. As an adjunct to diet it treats high cholesterol, familial hypercholesterolemia, and certain triglyceride disorders, and it reduces the risk of major cardiovascular events in people at increased risk.
This page is based on the FDA labeling for rosuvastatin, cross-checked with MedlinePlus and the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
The liver is a factory that manufactures cholesterol around the clock, and HMG-CoA reductase is the foreman of the production line. Rosuvastatin sends the foreman home, so the factory slows output; sensing the shortage, the liver pulls more LDL cholesterol out of the bloodstream to keep itself supplied, and blood levels fall.
In simple terms
Most cholesterol in the blood is made by the liver. Rosuvastatin selectively blocks HMG-CoA reductase, the enzyme the liver needs to produce cholesterol, stopping the conversion of HMG-CoA to mevalonate, an early building block. When the liver makes less cholesterol, it responds by taking up more LDL cholesterol from the blood, which lowers the level that can build up in artery walls. This is why statins reduce heart attacks and strokes, not just cholesterol numbers.
In depth
Rosuvastatin is the calcium salt of a statin with antilipidemic activity. It selectively and competitively binds to and inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyses the conversion of HMG-CoA to mevalonate, a precursor of cholesterol. This leads to a decrease in hepatic cholesterol levels and an increase in uptake of LDL cholesterol from the circulation. Rosuvastatin also lowers triglycerides in hypertriglyceridemia and is used across primary hyperlipidemia, familial hypercholesterolemia, and cardiovascular risk reduction settings.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How rosuvastatin lowers LDL cholesterol
- Rosuvastatin is the calcium salt of a statin with antilipidemic activity.
- It selectively and competitively binds to and inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyses the conversion of HMG-CoA to mevalonate, a precursor of cholesterol.
- This leads to a decrease in hepatic cholesterol levels and an increase in uptake of LDL cholesterol from the circulation.
- Rosuvastatin also lowers triglycerides in hypertriglyceridemia and is used across primary hyperlipidemia, familial hypercholesterolemia, and cardiovascular risk reduction settings.
Target: HMG-CoA reductase
The rate-limiting enzyme of cholesterol synthesis in the liver; inhibiting it lowers the liver's cholesterol output and prompts the liver to clear more LDL cholesterol from the blood.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- To reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of cardiovascular disease based on age, high-sensitivity C-reactive protein of 2 mg/L or higher, and at least one additional cardiovascular risk factor
- As an adjunct to diet, to reduce low-density lipoprotein cholesterol in adults with primary hyperlipidemia
- As an adjunct to diet, to reduce low-density lipoprotein cholesterol and slow the progression of atherosclerosis in adults
- As an adjunct to diet, to reduce low-density lipoprotein cholesterol in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia
- As an adjunct to other low-density lipoprotein cholesterol-lowering therapies, or alone if such treatments are unavailable, to reduce low-density lipoprotein cholesterol in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia
- As an adjunct to diet, for the treatment of adults with primary dysbetalipoproteinemia or hypertriglyceridemia
Official sources
The statements on this page trace back to these records.
- DailyMed: rosuvastatin official US label
U.S. National Library of Medicine, DailyMed
- U.S. Food and Drug Administration: rosuvastatin prescribing information
U.S. Food and Drug Administration
- MedlinePlus: rosuvastatin
MedlinePlus, U.S. National Library of Medicine
- National Cancer Institute: rosuvastatin calcium
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.